Biocon Limited has informed the Exchange regarding a press release dated December 02, 2025, titled "Biocon Biologics Secures Market Entry Date for Denosumab Biosimilars in Europe and Rest of the World®".
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Biocon Limited has shared a press release from December 2, 2025, announcing that its subsidiary Biocon Biologics has secured a confirmed market entry date for its Denosumab biosimilars across Europe and other international markets (Rest of the World). Denosumab biosimilars are used to treat conditions such as osteoporosis, bone metastases, and giant cell tumor of bone. Securing a market entry date means the product can now be launched on a defined timeline in these regions, marking a key commercial milestone for the biosimilar portfolio. This expands Biocon Biologics' reach beyond its existing biosimilar offerings in global markets.
Positive for shareholders — a confirmed market entry date paves the way for near-term revenue contribution from Denosumab biosimilars in Europe and other regulated markets, strengthening the subsidiary's growth outlook and adding to Biocon's long-term earnings potential.